ChanBio

Biopharmaceuticals for Treatment of Multiple Sclerosis

Health Tech & Life Sciences
Non Active, Dec 2016

Company Overview

Snapshot

Founded in January 2012 by Oren Bogin, ChanBio operates with 1–10 employees. The company has secured funding across two rounds from two investors. In November 2013, ChanBio joined the Merck Serono Israel Bioincubator.

Business overview

ChanBio is a biopharmaceutical company focused on developing functional antibody-based modulators that target ion channels and G-protein-coupled receptors (GPCRs). The company's core technology is applied to create treatments for multiple sclerosis, as well as other autoimmune, cardiovascular, cancer-related, and pain disorders. Operating within the Health Tech & Life Sciences sector, ChanBio serves the biopharmaceutical industry in markets such as the United States.

Strategic signal

In November 2013, ChanBio joined the Merck Serono Israel Bioincubator, a move that provided the biopharmaceutical startup with critical early-stage support and resources. This signals strategic validation from a major pharmaceutical entity, indicating potential for accelerated research and development within a structured innovation ecosystem.

Company Intelligence Q&A

When was ChanBio founded?
ChanBio was founded in January 2012.
Who is the founder of ChanBio?
Oren Bogin is the Founder & CEO of ChanBio.
What is ChanBio's primary focus?
ChanBio is dedicated to the development of functional antibody-based modulators active on ion channels and G-protein-coupled receptors (GPCRs) for treating conditions like multiple sclerosis, autoimmune, cardiovascular, cancer-related, and pain disorders.
When did ChanBio join the Merck Serono Israel Bioincubator?
In November 2013, ChanBio joined the Merck Serono Israel Bioincubator.